Zevalin Policy

Purpose

To describe the CVS Radiation Oncology External Policy for Zevalin.

Scope

The scope of this document applies to CVS Health clients who have signed up for the CVS Radiation Oncology program under CVS Health Solutions. This document includes the external policy details for the Zevalin policy.

Policy

Criteria for Initial Approval

A. Relapsed or Refractory, Low-grade or Follicular Non-Hodgkin's Lymphoma (NHL)

- CVS Health considers ibritumomab tiuxetan (Zevalin) medically necessary for treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL).

B. Previously Untreated Follicular NHL

- CVS Health considers ibritumomab tiuxetan (Zevalin) medically necessary for previously untreated follicular NHL in members who have achieved a partial or complete response to first-line chemotherapy.
- CVS Health considers all other indications as experimental and investigational (for additional information, see Experimental and Investigational and Background sections).

Continuation of Therapy

See Dosage and Administration information.

Procedure

Dosage and Administration

Ibritumomab tiuxetan (Zevalin) is available for injection as 3.2 mg ibritumomab tiuxetan per 2 mL as a clear, colorless solution, that may contain translucent particles, in a single-dose vial for intravenous use.

Relapsed or Refractory, Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma (NHL) or Previously Untreated Follicular NHL

The Zevalin therapeutic regimen consists of two distinct steps; step 1 involves an infusion of rituximab and step 2, 7 to 9 days later, consists of a second infusion of rituximab followed by yttrium-90 (Y-90) ibritumomab tiuxetan.

- Day 1: Administer rituximab 250 mg/m^2 intravenous infusion.
- Day 7, 8, or 9: Administer rituximab 250 mg/m^2 intravenous infusion:
- If platelets at least 150,000/mm^3: within 4 hours after rituximab infusion, administer 0.4 mCi/kg (14.8 MBq per kg) Y-90 Zevalin intravenous infusion;
- If platelets 100,000 to 149,000/mm^3 in relapsed or refractory persons: within 4 hours after rituximab infusion, administer 0.3 mCi/kg (11.1 MBq per kg) Y-90 Zevalin intravenous infusion.
- Initiate the Zevalin therapeutic regimen following recovery of platelet counts to 150,000/mm^3 or more at least 6 weeks, but no more than 12 weeks, following the last dose of first-line chemotherapy.
- Only administer Rituxan/Zevalin in facilities where immediate access to resuscitative measures is available.
- Do not administer Zevalin regimen to members with platelet counts less than 100,000 cells/mm^3.
- The maximum allowable dose of Y-90 Zevalin is 32.0 mCi (1184) MBq regardless of the member's body weight.

Source: Acrotech, 2019

Experimental and Investigational or Not Medically Necessary

CVS Health considers ibritumomab tiuxetan (Zevalin) not medically necessary when given as a repeat course of treatment.

CVS Health considers the ibritumomab tiuxetan (Zevalin) therapeutic regimen experimental and investigational for the treatment of all other indications including the following (not an all-inclusive list) because its effectiveness for these indications has not been established:

- Burkitt lymphoma
- Chronic lymphocytic leukemia
- Gastric MALT lymphoma
- Hepatocellular carcinoma
- Mantle cell lymphoma
- Nodal marginal zone lymphoma
- Nongastric MALT lymphoma
- Post-transplantation lymphoproliferative disorders
- Splenic marginal zone lymphoma.

References

The Zevalin policy is based on the following references:

1. Abdalla EK, Stuart KE, Singal AG. Overview of treatment approaches for hepatocellular carcinoma. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed July 2023.
2. Acrotech Biopharma LLC. Zevalin (ibritumomab tiuxetan) injection, for intravenous use. Prescribing Information. East Windsor,NJ: Acrotech; revised September 2019.
3. Ansell SM, Armitage J. Non-Hodgkin lymphoma: Diagnosis and treatment. Mayo Clin Proc. 2005;80(8):1087-1097.
4. Arranz R, García-Noblejas A, Grande C, et al. First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group. Haematologica. 2013;98(10):1563-1570.
5. Center for Medicare & Medicaid Services (CMS). Decision memo for radioimmunotherapy for non-Hodgkin's lymphoma (CAG-00163N). Medicare Coverage Database. Baltimore, MD: CMS; July 25, 2005.
6. Chahoud J, Sui D, Erwin WD, et al. Updated results of rituximab pre- and post-BEAM with or without 90yttrium ibritumomab tiuxetan during autologous transplant for diffuse large B-cell lymphoma. Clin Cancer Res. 2018;24(10):2304-2311.
7. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood. 2003;101(2):391-298.
8. Chow VA, Cassaday RD, Gooley TA, et al. Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma. Blood Adv. 2022;6(1):37-45.
9. Cullen M, Dixon A, Goldstone AH, et al.; British Committee for Standards in Haematology, Haematology-Oncology Task Force. Nodal non-Hodgkin's lymphoma. Guidelines on Diagnosis and Therapy. London, UK: British Committee for Standards in Haematology; August 2002.
10. Desai S, Moustafa MA, Wiseman G, Witzig T. Ibritumomab tiuxetan radioimmunotherapy for primary gastrointestinal follicular lymphoma. Oncologist. 2021;26:1-3.
11. Gibson AD. Updated results of a phase III trial comparing Ibritumomab tiuxetan with rituximab in previously treated patients with non-Hodgkin's lymphoma. Clin Lymphoma. 2002;3(2):87-89.
12. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin's lymphoma: A multivariable cohort analysis. Blood. 2003;102(7):2351-2357.
13. Hertzberg M, Gandhi MK, Trotman J, et al; Australasian Leukaemia Lymphoma Group (ALLG). Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse

large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica. 2017;102(2):356-363.
14. IDEC Pharmaceuticals. Zevalin (ibritumomab tiuxetan) prescribing information. San Diego, CA: IDEC; January 2002.
15. Iino M, Sakamoto Y, Sato T. Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy after induction chemotherapy in patients with indolent non-Hodgkin lymphoma: A single-institution experience. Hematology. 2019;24(1):623-630.
16. Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007;48(11):1767-1176.
17. Jain N, Wierda W, Ferrajoli A, et al. A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer. 2009;115(19):4533-4539.
18. Jurczak W, M Gruszka A, Sowa Staszczak A, et al. Consolidation with 90Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: Results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up. Leuk Lymphoma. 2019;60(11):2689-2696.
19. Karmali R, Larson ML, Shammo JM, et al. Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma. Mol Clin Oncol. 2017;6(4):627-633.
20. Koechli V, Klaeser B, Banz Y, et al. Consolidation of first remission using radioimmunotherapy with yttrium-90-ibritumomab-tiuxetan in adult patients with Burkitt lymphoma. Leuk Res. 2015;39(3):307-310.
21. Kolstad A, Laurell A, Jerkeman M, et al; Nordic Lymphoma Group. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood. 2014;123(19):2953-2959.
22. Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(1):90-95.
23. Lugtenburg PJ, Zijlstra JM, Doorduijn JK, et al; Dutch HOVON group. Rituximab-PECC induction followed by (90) Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: Results from a phase II HOVON study. Br J Haematol. 2019;187(3):347-355.
24. Maza S, Gellrich S, Assaf C, et al. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: First results of a prospective, monocentre study. Leuk Lymphoma. 2008;49(9):1702-1709.
25. Mei M, Palmer J, Tsai NNC, et al. Results of a phase II trial of allogeneic hematopoietic stem cell transplantation using 90Y-ibritumomab tiuxetan (Zevalin) in combination with fludarabine and melphalan in patients with high-risk B-cell non-Hodgkin's lymphoma. Clin Lymphoma Myeloma Leuk. 2023 May 23 [Online ahead of print].
26. Mondello P, Steiner N, Willenbacher W, et al. 90Y-ibritumomab-tiuxetan consolidation therapy for advanced-stage mantle cell lymphoma after first-line

autologous stem cell transplantation: Is it time for a step forward? Clin Lymphoma Myeloma Leuk. 2016;16(2):82-88.
27. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26(32):5156-5164.
28. Moustafa MA, Borah BJ, Moriarty JP, et al. Yttrium-90 ibritumomab tiuxetan is cost-effective compared to bendamustine + rituximab in low-grade lymphomas. Clin Lymphoma Myeloma Leuk. 2023;23(4):259-265.
29. Moustafa MA, Peterson J, Hoppe BS, et al. Real world long-term follow-up experience with yttrium-90 ibritumomab tiuxetan in previously untreated patients with low-grade follicular lymphoma and marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2022;22(8):618-625.
30. Nachtnebel A. Ibritumomab tiuxetan (Zevalin) as consolidation therapy after first remission in patients with follicular lymphoma. Decision Support Document: Horizon Scanning in Oncology Vol. 5. Vienna, Austria: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA); 2009.
31. National Comprehensive Cancer Network (NCCN). Ibritumomab tiuxetan. NCCN Drugs & Biologics Compendium. Plymouth Meeting, PA: NCCN; February 2023.
32. National Horizon Scanning Centre (NHSC). Ibritumomab tiuxetan for NHL -- horizon scanning review. New and Emerging Technology Briefing. Birmingham, UK: National Horizon Scanning Centre (NHSC); 2002.
33. No authors listed. Ibritumomab tiuxetan (Zevalin) for non-Hodgkin's lymphoma. Med Lett Drugs Ther. 2002;44(1144):101-102.
34. Otte A. Diagnostic imaging prior to 90Y-ibritumomab tiuxetan (Zevalin) treatment in follicular non-Hodgkin's lymphoma. Hell J Nucl Med. 2008;11(1):12-15.
35. Pandit-Taskar N, Hamlin PA, Reyes S, et al. New Strategies in radioimmunotherapy for lymphoma. Curr Oncol Rep. 2003;5(5):364-371.
36. Pohar R, Clark M, Nkansah E. Radioimmunotherapies for non-Hodgkin lymphoma: Systematic review of clinical effectiveness, cost-effectiveness, and guidelines. Health Technology Assessment Rapid Review. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health (CADTH); 2009.
37. Pouget JP, Navarro-Teulon I, Bardies M, et al. Clinical radioimmunotherapy -- the role of radiobiology. Nat Rev Clin Oncol. 2011;8(12):720-734.
38. Rossignol J, Terriou L, Robu D, et al. Radioimmunotherapy ((90) Y-ibritumomab tiuxetan) for posttransplant lymphoproliferative disorders after prior exposure to rituximab. Am J Transplant. 2015;15(7):1976-1981.
39. Sgouros G, Squeri S, Ballangrud AM, et al. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: Assessment of tumor dose-response. J Nucl Med. 2003;44(2):260-268.
40. Shimoni A, Zwas ST, Oksman Y, et al. Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma. Bone Marrow Transplant. 2008;41(4):355-361.
41. Song H, Sgouros G. Radioimmunotherapy of solid tumors: Searching for the right target. Curr Drug Deliv. 2011;8(1):26-44.

42. Spectrum Pharmaceuticals, Inc. Zevalin (ibritumomab tiuxetan) injection for intravenous use. Prescribing Information. Irvine, CA: Spectrum Pharmaceuticals, revised August 2013.
43. Tennvall J, Fischer M, Bischof Delaloye A, et al; Therapy Committee, EANM; Oncology Committee, EANM; Dosimetry Committee, EANM. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging. 2007;34(4):616-622.
44. U.S. Food and Drug Administration, Office of Public Affairs. FDA approves first radiopharmaceutical product to treat non-Hodgkin's lymphoma. T02-11. FDA Talk Paper. Rockville, MD: FDA; February 19, 2002.
45. Vaklavas C, Meredith RF, Shen S, et al. Phase I study of a modified regimen of 90-Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma. Cancer Biother Radiopharm. 2013;28(5):370-379.
46. Wang M, Oki Y, Pro B, et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27(31):5213-5218.
47. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood. 2002;99(12):4336-4342.
48. Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials. J Nucl Med. 2003;44(3):465-474.
49. Wiseman GA, Leigh BR, Erwin WD, et al. Radiation dosimetry results from a phase II trial of ibritumomab tiuxetan (Zevalin trade mark) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm. 2003;18(2):165-178.
50. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol. 2001;39(1-2):181-194.
51. Wiseman GA, White CA, Stabin M, et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med. 2000;27(7):766-777.
52. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20(15):3262-3269.
53. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20(10):2453-2463.

54. Witzig TE, Hong F, Micallef IN, et al. A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402. Br J Haematol. 2015;170(5):679-686.
55. Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109(9):1804-1810.
56. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21(7):1263-1270.
57. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17(12):3793-3803.
58. Witzig TE, Wiseman GA, Maurer MJ, et al. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. Am J Hematol. 2013;88(7):589-593.
59. Zinzani PL, d'Amore F, Bombardieri E, et al. Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. Eur J Cancer. 2008;44(3):366-373.